

# EPICS

**Conference Coverage: ASH 2024 – Focus on CAR T**  
**December 13, 2024; 15.00 – 18.30 CET / 9.00 AM – 12.30 PM EST**  
 Virtual Meeting

**Chair:** Marie José Kersten, MD, PhD (Netherlands)

**Proposed Faculty**

MM: Mohamad Mohty, MD (France) – PENDING  
 ALL: Jae Park, MD (US)  
 DLBCL: Gilles Salles, MD, PhD (US)  
 Indolent NHL and MCL: Caron Jacobson, MD, MMSc (US)  
 New developments including CLL: Michael Hudecek, MD (Germany) – PENDING

**NOTE:** This agenda does not yet include any potential LBA

| Time (CET)                           | Topic   | Speaker                     |
|--------------------------------------|---|-----------------------------|
| 15.00 – 15.10 /<br>9.00 AM – 9.10 AM | <b>Welcome and Introductions</b>  | Marie José Kersten, MD, PhD |
| <b>Update on CAR T in MM</b>         |   |                             |
| 15.10 – 15.25 /<br>9.10 AM – 9.25 AM | <b>Ongoing Late-Phase Studies</b> <ul style="list-style-type: none"> <li>• <b>1027</b> <a href="#">Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucl in High-Risk Smoldering Myeloma</a> – <b>Nadeem O, et al</b></li> <li>• <b>1031</b> <a href="#">Phase 2 Registrational Study of Anitocabtagene Autoleucl for the Treatment of Patients with RRMM: Preliminary Results from the IMMagine-1 Trial</a> – <b>Freeman CL, et al</b></li> <li>• <b>1032</b> <a href="#">Ciltacabtagene Autoleucl Vs SOC in Patients with Lenalidomide-Refractory MM after 1-3 Lines of Therapy: MRD Negativity in the Phase 3 Cartitude-4 Trial</a> – <b>Popat R, et al</b></li> </ul> <b>Real-World Data</b> <ul style="list-style-type: none"> <li>• <b>936</b> <a href="#">Comparative Safety and Efficacy of Ciltacabtagene Autoleucl and Idecabtagene Vicleucl CAR T-Cell Therapies in RRMM</a> – <b>Hansen DK, et al</b></li> <li>• <b>931</b> <a href="#">Talquetamab Bridging: Paving the Way to BCMA CAR T-Cell Therapy in RRMM</a> – <b>Dhakai B, et al</b></li> </ul> | Mohamad Mohty, MD           |

|  |  |   |
|--|--|---|
| <p>15.25 – 15.35 /<br/>9.25 AM – 9.35 AM</p>   | <p><b>Ongoing Early-Phase Studies</b></p> <ul style="list-style-type: none"> <li>• <a href="#">923 A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with RRMM Including Those with Extramedullary Disease</a> – <b>Jiang H, et al</b></li> <li>• <a href="#">1030 Efficacy of HBI0101, an Anti-BCMA CART for RRMM</a> – <b>Lebel E, et al</b></li> <li>• <a href="#">1029 CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease - an <i>In Vivo</i> Imaging and Molecular Monitoring Study (CARMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI</a> – <b>Dowling MR, et al</b></li> <li>• <a href="#">922 Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a GPRC5D Targeted CAR T Cell Therapy in Patients with Heavily Pretreated RRMM</a> – <b>Bal S, et al</b></li> </ul>  | <p>Michael Hudecek, MD</p>  |
| <p>15.35 – 16.15 /<br/>9.35 AM – 10.15 AM</p>  | <p><b>Discussion</b></p> <ul style="list-style-type: none"> <li>• In your opinion, what are the most impactful data on CAR T-cell therapy in MM presented at ASH 2024? <ul style="list-style-type: none"> <li>– How will you incorporate these new data into your current treatment approach for MM?</li> </ul> </li> <li>• What is your perception of the CARTITUDE-4 trial updates?</li> <li>• What is your impression of the CAR-PRISM study in high-risk smoldering myeloma? <ul style="list-style-type: none"> <li>– Do you think CAR T is feasible in other high-risk precursor cancer settings?</li> </ul> </li> <li>• What is your perception of the preliminary results from the IMMagine-1 trial?</li> <li>• What new developments in MM do you believe are most promising?</li> <li>• How do you currently sequence CAR T-cell therapy and bispecific antibodies in MM? Do any of the presented data change your approach?</li> <li>• What challenges remain for uptake of CAR T in MM?</li> <li>• What unmet needs remain with CAR T in MM?</li> </ul> | <p>All</p> <p>Discussion moderated by Marie José Kersten, MD, PhD</p> |
| <p>16.15 – 16.20 /<br/>10.15 AM – 10.20 AM</p> | <p><b>Summary of Key Takeaways</b></p>   | <p>Mohamad Mohty, MD, and Michael Hudecek, MD</p>                     |
| <p><b>Update on CAR T in NHL</b></p>           |  |   |
| <p>16.20 – 16.40 /<br/>10.20 AM – 10.40 AM</p> | <p><b>Aggressive NHL</b></p> <ul style="list-style-type: none"> <li>• <a href="#">67 Rapcabtagene Autoleucel (YTB323) in Patients with R/R DLBCL: Phase II Trial Clinical Update</a> – <b>Riedell PA, et al</b></li> <li>• <a href="#">68 Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells</a> – <b>Zamtocabtagene</b></li> </ul>   | <p>Gilles Salles, MD, PhD</p>   |

|  |  |   |
|--|--|---|
|  | <p><a href="#">Autoleucl in Patients with R/R DLBCL</a>– <b>Shah NN, et al</b></p> <ul style="list-style-type: none"> <li>• <b>93</b> <a href="#">Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of R/R NHL</a> – <b>Kersten MJ, et al</b></li> <li>• <b>748</b> <a href="#">Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucl in Patients with R/R MCL Who Were Naive to BTKi</a> – <b>van Meerten T, et al</b></li> <li>• <b>91</b> <a href="#">Rituximab, Lenalidomide, and Zanubrutinib With Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma</a> – <b>Zhang M, et al</b></li> </ul> <p><b>Indolent NHL</b></p> <ul style="list-style-type: none"> <li>• <b>864</b> <a href="#">5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucl in Patients with R/R iNHL</a> – <b>Neelapy SS, et al</b></li> </ul>   |   |
| <p>16.40 – 17.00 /<br/>10.40 AM – 11.00 AM</p> | <p><b>Real-World Data</b></p> <ul style="list-style-type: none"> <li>• <b>470</b> <a href="#">RW Outcomes of Lisocabtagene Maraleucl As Second-Line Therapy in Patients with R/R LBCL: First Results from the CIBMTR Registry</a> – <b>Odstrcil Bobillo MS, et al</b></li> <li>• <b>472</b> <a href="#">RW Outcomes of Lisocabtagene Maraleucl in Patients with R/R LBCL and Secondary CNS Involvement from the CIBMTR Registry</a> – <b>Ahmed S, et al</b></li> <li>• <b>607</b> <a href="#">Tisagenlecleucl for the Management of Patients with R/R DLBCL: An Interim Report of the European Post-Authorisation Safety Study Conducted by EBMT</a>– <b>Montoto S, et al</b></li> <li>• <b>71</b> <a href="#">Real-World Comparison of Efficacy and Safety of Fludarabine- Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 CAR T-Cell Therapy in R/R LBCL</a>– <b>Ali A, et al</b></li> <li>• <b>610</b> <a href="#">Temporal Association and Risk Window for Secondary Malignancies Post CAR T</a> – <b>Cho H, et al</b></li> <li>• <b>612</b> <a href="#">Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed CART As Second Versus Later Line of Therapy</a> – <b>Elisworth BL, et al</b></li> </ul> | <p>Caron Jacobson, MD, MMSc</p>                                       |
| <p>17.00 – 17.40 /<br/>11.00 AM – 11.40 AM</p> | <p><b>Discussion</b></p> <ul style="list-style-type: none"> <li>• In your opinion, what are the most impactful data on CAR T-cell therapy in aggressive and indolent NHL presented at ASH 2024? <ul style="list-style-type: none"> <li>– How will you incorporate these new data into your current treatment approach for aggressive and indolent NHL?</li> </ul> </li> <li>• What is your perception of the primary analysis of ZUMA-2 cohort 3?</li> </ul>   | <p>All</p> <p>Discussion moderated by Marie José Kersten, MD, PhD</p> |

|  |  |  |
|--|--|--|
|  | <ul style="list-style-type: none"> <li>• How do you see the future of treatment sequencing in DLBCL? Will HSCT be replaced by CAR T? If not, how will they survive together?</li> <li>• Are we ready for outpatient CAR T? Which patients, and which CAR Ts?</li> <li>• Can you comment on the risk of secondary T-cell malignancies associated with CAR T-cell therapy? <ul style="list-style-type: none"> <li>- What do you believe are the next steps for the medical community in ensuring that CAR T-cell therapy remains a safe and effective treatment option for lymphoma and other blood cancers?</li> </ul> </li> <li>• In DLBCL and lymphoma in general, what do you foresee in the future for <ul style="list-style-type: none"> <li>- Allogeneic CAR Ts?</li> <li>- Bispecific CAR Ts?</li> <li>- CAR-NKs?</li> <li>- Others?</li> <li>- What is the current status of each of these approaches?</li> </ul> </li> <li>• What unmet needs remain with CAR T in aggressive lymphoma?</li> <li>• What unmet needs remain with CAR T in indolent lymphoma?</li> </ul> |  |
| 17.40 – 17.45 /<br>11.40 AM – 11.45 AM | <b>Summary of Key Takeaways</b>  | Gilles Salles, MD, PhD, and Caron Jacobson, MD, MMSc |
| 17.45 – 17.50 /<br>11.45 AM – 11.50 AM | <b>BREAK</b>   |  |
| <b>Updates on CAR T in Leukemia</b>    |  |  |
| 17.50 – 18.05 /<br>11.50 AM – 12.05 PM | <p><b>ALL</b></p> <ul style="list-style-type: none"> <li>• <b>963</b> <a href="#">Obecabtagene autoleucel for Adult R/R B-ALL: Deep Molecular Remission May Predict Better Outcomes</a> – <b>Jabbour E, et al</b></li> <li>• <b>965</b> <a href="#">Second Infusion of CAR T-Cells in Patients with R/R B-ALL: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT</a> – <b>Rives S, et al</b></li> <li>• <b>681</b> <a href="#">Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell ALL</a> – <b>Wan X, et al</b></li> </ul> <p><b>AML</b></p> <ul style="list-style-type: none"> <li>• <b>369</b> <a href="#">Autologous CD33CART for Children and Adolescents/Young Adults with R/R AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent <i>in Vitro</i>, <i>in Vivo</i>, and <i>Ex Vivo</i> Anti-Leukemia Activity</a> – <b>Balestra T, et al</b></li> </ul>  | Jae Park, MD   |
| 18.05 – 18.20 /<br>12.05 PM – 12.20 PM | <b>Discussion</b>  | All  |

|  |   |   |
|--|---|---|
|  | <ul style="list-style-type: none"> <li>• In your opinion, what are the most impactful data on CAR T-cell therapy in leukemia presented at ASH 2024? <ul style="list-style-type: none"> <li>– How will you incorporate these new data into your current treatment approach for ALL?</li> </ul> </li> <li>• How do you see the relationship between HSCT and CAR T evolving? What is your impression of consolidative HSCT post-CAR T?</li> <li>• Which approaches to limit CAR T-cell therapies' toxicity do you find the most promising?</li> <li>• What is your current bridging approach to CAR T in ALL?</li> <li>• What new developments with CAR T in ALL do you believe are most promising?</li> <li>• What is the status of CAR T in AML? What new development do you find most promising?</li> <li>• What unmet needs remain with CAR T in leukemia?</li> </ul> | Discussion moderated by Marie José Kersten, MD, PhD |
| 18.20 – 18.25 /<br>12.20 PM – 12.25 PM | <b>Summary of Key Takeaways</b>   | Jae Park, MD  |
| 18.25 – 18.30 /<br>12.25 PM – 12.30 PM | <b>Closing Remarks</b>  | Marie José Kersten, MD, PhD                         |